PhRMApedia Press Room
PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases. PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.
WASHINGTON (March 7, 2016) — America’s biopharmaceutical research companies are working to advance the treatment of osteoporosis with nine medicines in development, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Osteoporosis Foundation (NOF).
Nearly 54 million Americans live with osteoporosis or low bone density, and that number is expected to reach more than 71 million by 2030. What’s more, half of women and a quarter of men over the age of 50 are expected to break a bone as a result of osteoporosis. New treatments and innovations in development by biopharmaceutical companies are providing hope for these Americans and their families.
WASHINGTON, D.C. (March 1, 2016) – Today the Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk provided the following statement in reaction to a study published in BMJ on physician-administered drugs:
“Biopharmaceutical companies are committed to developing medicines that help patients live longer, healthier lives and, in recent decades, there have been tremendous advances in treatment options for patients including those with cancer, arthritis and hepatitis C.
BOSTON, MA – February 24, 2016 - Earlier today, representatives of local law enforcement and the Pharmaceutical Research and Manufacturers of America (PhRMA) were joined by Governor Charlie Baker at the Massachusetts State House to formally launch "MyOldMeds Massachusetts,” a public information campaign to drive awareness around safe prescription drug use, storage and disposal. The campaign also highlights existing resources for returning unused medicines to certain locations and provides information on substance abuse treatment options in the Commonwealth.
Washington D.C. (January 19, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Rodger Currie will join the association as executive vice president for advocacy. He will lead federal, state and international government affairs and alliance development. Currie returns to PhRMA on February 1, 2016.
Washington, DC (January 7, 2016) The Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Amy Jackson as its new representative in Japan. As PhRMA’s Japan Representative, Ms. Jackson will coordinate the activities of PhRMA’s office in Tokyo and advocate for America’s research-based pharmaceutical companies on government, economic and health care policy matters in Japan.
Washington, D.C. (October 5, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John Castellani, issued the following statement:
“PhRMA believes that strong intellectual property protection is necessary for the discovery and development of new treatments and therapies for the world’s patients.
“We are disappointed that the Ministers failed to secure 12 years of data protection for biologic medicines, which represent the next wave of innovation in our industry. This term was not a random number, but the result of a long debate in Congress, which determined that this period of time captured the appropriate balance that stimulated research but gave access to biosimilars in a timely manner.
Washington D.C. (September 25, 2015) – The Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Stephen J. Ubl will be the next president and chief executive officer (CEO) of the association. Ubl joins PhRMA after more than ten years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), the world’s largest medical technology association. He succeeds John J. Castellani who announced earlier this year that he will be retiring at the end of the year.
Estas propuestas radicales y de largo alcance podrían restringir el acceso de los pacientes a los medicamentos, que resultan en menos nuevos tratamientos para los pacientes, costará innumerables puestos de trabajo en todo el país y erosionará la posición de nuestro país como el líder mundial en la innovación biomédica.
Washington, D.C. (22 de septiembre, 2015) – El presidente y CEO de la empresa de Pharmaceutical Research and Manufacturers of America (PhRMA) John J. Castellani, emitió hoy la siguiente declaración en respuesta a la propuesta lanzada por la Secretaria Clinton para regular los precios de medicamentos con receta:
These sweeping and far-reaching proposals would restrict patients’ access to medicines, result in fewer new treatments for patients, cost countless jobs across the country and erode our nation’s standing as the world leader in biomedical innovation.
Washington, D.C. (September 22, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO John J. Castellani today released the following statement in response to the proposal released by Secretary Clinton to regulate prescription drug prices:
WASHINGTON (September 10, 2015) — America’s biopharmaceutical research companies are currently working to develop 836 medicines and vaccines to treat a broad range of cancers, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) that highlights the American Association for Cancer Research (AACR) annual Cancer Progress Report.
WASHINGTON (September 9, 2015) — The Pharmaceutical Research and Manufacturers of America (PhRMA) this evening announced the recipients of the 2015 Research & Hope Awards, honoring researchers and patient advocates for their roles in advancing innovative biopharmaceutical research and improving patient care. This year’s awardees were recognized for their work in the fight against cancer, which claims the lives of more than seven million people worldwide every year.
WASHINGTON (Septiembre 1, 2015) - Hoy, la empresa de Investigación y Fabricantes Farmacéuticos de América (PhRMA) lanzaron el sitio AccessBetterCoverage.com/espanol, un centro de recursos en español sobre la atención de la salud, el seguro de salud y consejos para la compra de cobertura de salud.
WASHINGTON (September 1, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched Access BetterCoverage.org/espanol, a hub of Spanish-language resources on health care, health insurance and tips for shopping for health coverage.
The new site introduces important resources to help people better understand how health insurance works and what to expect from their coverage. The site includes a series of Spanish-language white board videos explaining basic insurance terms like deductibles, copays and coinsurance, and how formularies work as well as a glossary of health insurance terms and lists of questions to ask when picking a plan.
WASHINGTON, D.C. (July 31, 2015) —The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Rajesh Ranganathan, Ph.D. will join the organization as Vice President of Science and Regulatory Advocacy effective August 3, 2015.
“Rajesh’s experience in academia, the biopharmaceutical industry and government will be invaluable as he leads PhRMA’s ongoing efforts to promote innovation and enhanced efficiency in drug discovery and development,” stated Bill Chin, M.D., Executive Vice President of Science and Regulatory Advocacy.
Washington, D.C. (July 15, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Science and Regulatory Advocacy Sascha Haverfield, Ph.D., and Biotechnology Industry Organization (BIO) Senior Vice President of Science Policy Kay Holcombe released the following joint statement on the reauthorization of the Prescription Drug User Fee Act (PDUFA):
“For more than 20 years, PDUFA has helped the Food and Drug Administration (FDA) fulfill its central mission of protecting and promoting public health by allowing the Agency to keep pace with the rapid increase in the number and complexity of innovative drugs and biologics requiring regulatory review.